← Back to Clinical Trials
Recruiting NCT05058781

NCT05058781 Minipuberty in Infants Born With Potential Hypogonadism Hypogonadotrope

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05058781
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire Vaudois
Condition DSD
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2017-01-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 9 Months
Study Type OBSERVATIONAL
All Conditions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2017-01-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Disorders of sex development (DSD) occur in 1/3000 births and are defined by variation in aspect of external genital organs, e.g. cryptorchidism, hypospadias and micropenis in male infants and clitoral hypertrophy in female infants. Genetic, hormonal and environmental factors are implicated in DSD. Infants with congenital hypogonadism hypogonadotrope (CHH) can present with DSD. Evaluation of hormonal profile during minipuberty could be of great help to better characterize the etiology of DSD and CHH in particular. Our main objective is to study hormonal profile during the minipuberty of infants born with DSD or born from parents with CHH compared to controls.

Eligibility Criteria

Inclusion Criteria: * infants born with symptoms of DSD * infants born from parents with CHH Exclusion Criteria: * premature \< 35 weeks of gestation * male infants with high scrotal cryptorchidism

Contact & Investigator

Central Contact

Nelly Pitteloud, MD

✉ nelly.pitteloud@chuv.ch

📞 +41 79 556 27 36

Principal Investigator

Nelly Pitteloud, MD

PRINCIPAL INVESTIGATOR

CHUV

Frequently Asked Questions

Who can join the NCT05058781 clinical trial?

This trial is open to participants of all sexes, up to 9 Months, studying DSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05058781 currently recruiting?

Yes, NCT05058781 is actively recruiting participants. Contact the research team at nelly.pitteloud@chuv.ch for enrollment information.

Where is the NCT05058781 trial being conducted?

This trial is being conducted at Lausanne, Switzerland.

Who is sponsoring the NCT05058781 clinical trial?

NCT05058781 is sponsored by Centre Hospitalier Universitaire Vaudois. The principal investigator is Nelly Pitteloud, MD at CHUV. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology